The global protein A resin market is projected to reach USD 2.0 billion by 2030 from USD 1.5 billion in 2025, at a CAGR of 6.5% during the forecast period.
Market growth is attributed to increased outsourced services through CDMOs, with major players expanding multi-plant biomanufacturing capacities across developed markets. The global monoclonal antibody (mAb) pipeline is growing, marked by high FDA approvals and new bispecific and antibody-drug conjugate launches. This has helped boost purification requirements among end users, which is expected to increase the market for protein A resin.
Market growth is attributed to increased outsourced services through CDMOs, with major players expanding multi-plant biomanufacturing capacities across developed markets. The global monoclonal antibody (mAb) pipeline is growing, marked by high FDA approvals and new bispecific and antibody-drug conjugate launches. This has helped boost purification requirements among end users, which is expected to increase the market for protein A resin.
Based on product, bulk resins held the largest share of the protein A resin market in 2024.
Based on products, the protein A resin market is divided into bulk resin, pre-packed columns, lab-scale columns, and others. Unlike pre-packed formats, bulk resin is the industry standard for high-volume purification processes in stainless-steel column setups. While it requires in-house packing and validation, bulk resin provides a much lower cost per cycle and per gram of purified monoclonal antibody. It is the preferred choice among end users because of its reusability. Most types can support 50 to over 200 cycles, enabling long-term production runs with minimal resin replacement. This feature directly enhances the economic efficiency and productivity goals of commercial manufacturing. All these factors make bulk resin the favored choice in the end-use industries.Based on matrix type, the agarose-based protein A resin segment accounted for the largest share during the forecast period.
The protein A resin market is categorized by matrix type into agarose-based, glass/silica-based, and organic polymer-based varieties. Among these, agarose-based protein A resins represent the largest market share. They are known for their improved durability, stronger mechanical properties, and higher capacity to absorb metal dopants at suitable pH levels. Recent developments in agarose-based resins include next-generation products such as Praesto CH1 and DurA Cycle A50, which offer better durability, increased binding capacity, and improved compatibility with complex antibody formats like bispecifics and fragments. These new products feature engineered ligands with enhanced alkaline resistance, enabling longer reuse and better cost efficiency.Based on applications, the monoclonal antibodies purification segment has acquired the largest share in 2024.
Based on applications, the protein A resin market is divided into mAb purification, Fc-fusion protein purification, and other applications. mAb purification holds the largest share in the protein A resin market mainly because of its established role in large-scale biopharmaceutical manufacturing. mAbs are the most widely produced category of biologic therapeutics, requiring large amounts of protein A resin for the primary capture steps in downstream processing. Protein A resin is preferred due to its Fc region binding specificity and compliance with regulatory standards for product purity and consistency. Moreover, a significant portion of the installed biomanufacturing capacity across pharmaceutical companies and contract manufacturing organizations is dedicated to mAb production, which naturally increases demand for protein A resin in this segment.Based on end users, the pharmaceutical and biopharmaceutical companies segment accounted for the largest share in 2024.
Pharmaceutical and biopharmaceutical companies account for the major share in the protein A resin market due to their role as the primary manufacturers of therapeutic proteins, particularly monoclonal antibodies (mAbs) and Fc-fusion proteins. These companies operate large-scale production facilities where protein A resin is extensively used in downstream purification processes, requiring significant resin volumes to meet commercial supply needs and regulatory compliance standards. Additionally, in-house manufacturing setups within these organizations prioritize consistent supply chains and quality control, further reinforcing direct procurement of protein A resins rather than relying solely on outsourced partners. This structural reliance on protein A resin for core biologics manufacturing activities positions pharmaceutical and biopharmaceutical companies as the dominant end-user segment in the market.North America is expected to hold a significant market share in the protein A resin market throughout the forecast period.
The protein A resin market includes five main regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2024, North America held a significant market share for protein A resin. Its dominant position is due to increased manufacturing capacity, focusing on commercial-scale and clinical trial supply production. Investment trends show that US federal and state support promotes domestic biomanufacturing for pandemic preparedness and reducing reliance on international supply chains. Small- to mid-sized biotech firms are increasingly partnering with CDMOs. These factors have helped North America secure the largest market share in 2024.A breakdown of the primary participants referred to for this report is provided below:
- By Company Type: Tier 1 (35%), Tier 2 (45%), and Tier 3 (20%)
- By Designation: C-level Executives (35%), Directors (25%), and Others (40%)
- By Region: North America (40%), Europe (30%), Asia Pacific (20%), Latin America (5%), and the Middle East & Africa (5%)
Research Coverage
The research report analyzes the protein A resin market by product, matrix type, source, application, end user, and region. It explores the factors driving market growth, examines the challenges and opportunities faced by various industries, and presents details on the competitive landscape, including market leaders and small to medium-sized enterprises. Additionally, it estimates the revenue generated by different market segments across five regions and includes a micromarket analysis.Reasons to Buy the Report
The report will help market leaders and new entrants by providing accurate revenue estimates for the protein A resin market and subsegments. It will assist stakeholders in understanding the competitive landscape, enabling them to position their businesses more effectively and develop suitable go-to-market strategies. Additionally, the report offers insights into market dynamics, including key drivers, restraints, challenges, and opportunities.This report provides insightful data on the following pointers:
- Market Penetration: In-depth coverage of product portfolios offered by the top players in the protein A resin market.
- Product Development/Innovation: In-depth coverage of product portfolios offered by the top players in the protein A resin market.
- Market Development: Insightful data on profitable developing areas.
- Market Diversification: Details about recent developments and advancements in the protein A resin market.
- Competitive Assessment: Extensive assessment of the products, growth tactics, revenue projections, and market categories of the top competitors.
Table of Contents
1 Introduction
2 Research Methodology
4 Premium Insights
5 Market Overview
6 Protein a Resin Market, by Product
7 Protein a Resin Market, by Source
8 Protein a Resin Market, by Matrix Type
9 Protein a Resin Market, by Application
10 Protein a Resin Market, by End-user
11 Protein a Resin Market, by Region
12 Competitive Landscape
13 Company Profiles
14 Appendix
List of Tables
List of Figures
Companies Mentioned
- Danaher
- Thermo Fisher Scientific Inc.
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc
- Merck KGaA
- Repligen Corporation
- Tosoh Bioscience
- Ecolab Inc.
- Novasep Holding
- Avantor, Inc.
- Orochem Technologies, Inc.
- Kaneka Corporation
- Jsr Corporation
- Genscript
- Bio-Works
- Geno Technology, Inc.
- Promega Corporation
- Suzhou Nanomicro Technology Co. Ltd.
- Transgen Biotech Co. Ltd
- Resyn Biosciences (Pty) Ltd
- Biotoolomics Ltd.
- Calibre Scientific (Protein Ark)
- Sunresin New Materials Co. Ltd.
- Beaver
